Ocumension Therapeutics (HKG:1477)

Market Cap	5.63B +68.1%
Revenue (ttm)	595.79M +75.2%
Net Income	-273.13M
EPS	-0.36
Shares Out	815.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	608,500
Average Volume	1,111,619
Open	6.88
Previous Close	6.90
Day's Range	6.78 - 7.00
52-Week Range	3.91 - 12.23
Beta	0.51
RSI	40.86
Earnings Date	Mar 27, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related mac...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 505
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1477

Financial Performance

In 2024, Ocumension Therapeutics's revenue was 417.31 million, an increase of 69.38% compared to the previous year's 246.37 million. Losses were -268.27 million, -29.36% less than in 2023.

Financial numbers in CNY